Lipid compositions with high DHA content
The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
1. A method for treating type II diabetes comprising orally administering to a subject diagnosed with the type II diabetes an effective amount of a lipid composition comprising a phospholipid extract from immature herring roe, and a carrier oil, wherein:
the phospholipid extract comprises less than about 1 wt. % free fatty acids; less than 0.5 wt. % arachidonic acid; at least about 75 wt. % phosphatidylcholine; at least about 40% of the total fatty acids of the phospholipid extract are docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of DHA to EPA is at least about 1.5:1; a ratio of total omega-3 fatty acids to total omega-6 fatty acids of 22.7:1; and a maximum mercury concentration of about 0.01 mg/kg;
the carrier oil comprises mono-, di- or triglycerides; fatty acid ethyl esters; free fatty acids; phospholipids; or a combination thereof; and
the lipid composition comprises about 20 wt. % to about 90 wt. % of the phospholipid extract and about 10 wt. % to about 80 wt. % carrier oil, and the composition is free of shellfish antigens;
wherein the administration is approximately daily for an effective amount of time to reduce the severity of the type II diabetes, thereby treating or reducing the symptoms of the type II diabetes.
2. The method of claim 1 wherein the phospholipid extract comprises omega-3 phospholipids and the omega-3 phospholipids comprise one or more of lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine and lysophosphatidylinositol.
3. The method of claim 1 wherein the ratio of DHA to EPA in the phospholipid extract is at least about 2:1.
4. The method of claim 3 wherein the ratio of DHA to EPA in the phospholipid extract is about 2.2:1 to about 3.5:1.
5. The method of claim 1 wherein the lipid composition is administered in combination with the mineral zinc.
6. The method of claim 1 wherein the lipid composition is administered as part of a dietary supplement, nutritional supplement, pharmaceutical product, or food product.
7. The method of claim 6 wherein the supplement or product comprises a fish protein additive.
8. The method of claim 7 wherein the fish protein additive comprises a fish protein hydrolysate or fish protein-derived amino acids.
9. The method of claim 1 wherein the lipid composition comprises about 50 wt. % carrier oil.
10. The method of claim 1 wherein the lipid composition comprises about 20 wt. % carrier oil.
11. The method of claim 1 wherein the carrier oil comprises fish oil, vegetable oil, microbial oil, or a combination thereof.
12. The method of claim 1 wherein the phospholipid extract has a maximum concentration of dioxins and furans of about 2.0 mg/kg and a maximum concentration of PCBs of about 0.09 mg/kg.
13. The method of claim 1 wherein the phospholipid extract comprises 19.2% palmitic acid, 5.6% palmitoleic acid, 8.4% oleic acid, 12.8% EPA, and 31.3% DHA, based on relative amounts.
14. A method for reducing insulin resistance comprising orally administering to a subject diagnosed with the insulin resistance an effective amount of a lipid composition consisting essentially of phospholipid extract from immature herring roe, and a carrier oil, wherein:
the phospholipid extract comprises 19.2% palmitic acid, 5.6% palmitoleic acid, 8.4% oleic acid, 12.8% EPA, and 31.3% DHA, based on relative amounts;
the phospholipid extract comprises less than about 1 wt. % free fatty acids; at least about 75 wt. % phosphatidylcholine; at least about 40% of the total fatty acids of the phospholipids are docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of DHA to EPA is at least about 1.5:1; and a ratio of total omega-3 fatty acids to total omega-6 fatty acids of 22.7:1;
the carrier oil comprises mono-, di- or triglycerides; fatty acid ethyl esters; free fatty acids; phospholipids; or a combination thereof; and
the lipid composition comprises about 20 wt. % to about 90 wt. % of the phospholipid extract and about 10 wt. % to about 80 wt. % carrier oil, and the composition is free of shellfish antigens;
wherein the administration is approximately daily for an effective amount of time to reduce the amount of insulin required by the subject, thereby reducing insulin resistance in the subject.
15. The method of claim 14 wherein the phospholipid extract comprises omega-3 phospholipids and the omega-3 phospholipids comprise one or more of lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine and lysophosphatidylinositol.
16. The method of claim 14 wherein the ratio of DHA to EPA in the phospholipid extract is at least about 2:1.
17. The method of claim 14 wherein the phospholipid extract has a maximum concentration of dioxins and furans of about 2.0 mg/kg and a maximum concentration of PCBs of about 0.09 mg/kg.
18. A method for treating type II diabetes comprising orally administering to a subject diagnosed with the type II diabetes an effective amount of a lipid composition comprising a phospholipid extract from immature herring roe, and a carrier oil, wherein:
the phospholipid extract comprises 19.2% palmitic acid, 5.6% palmitoleic acid, 8.4% oleic acid, 12.8% EPA, and 31.3% DHA, based on relative amounts;
the phospholipid extract comprises less than about 1 wt. % free fatty acids; at least about 75 wt. % phosphatidylcholine; at least about 40% of the total fatty acids of the phospholipid extract are docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA); and the ratio of DHA to EPA is at least about 1.5:1;
the carrier oil comprises mono-, di- or triglycerides; fatty acid ethyl esters; free fatty acids; phospholipids; or a combination thereof; and
the lipid composition comprises about 20 wt. % to about 90 wt. % of the phospholipid extract and about 10 wt. % to about 80 wt. % carrier oil, and the composition is free of shellfish antigens;
wherein the administration is approximately daily for an effective amount of time to reduce the severity of the type II diabetes, thereby treating or reducing the symptoms of the type II diabetes.
19. The method of claim 18 wherein the phospholipid extract comprises less than 0.5 wt. % arachidonic acid, a maximum mercury concentration of about 0.01 mg/kg, a maximum concentration of dioxins and furans of about 2.0 mg/kg, and a maximum concentration of PCBs of about 0.09 mg/kg.